Vaccine Response Articles & Analysis: Older
19 news found
CEPI will provide seed funding of up to US$4.8m to NEC OncoImmunity AS (NOI), a Norway-based subsidiary of NEC, which specializes in artificial intelligence-driven biotechnology, to support the initial development of broadly protective betacoronavirus vaccine candidates. NEC, through NOI, will lead a research consortium including the European Vaccine Initiative ...
Highly effective vaccines providing robust protection to people remains to be an unmet need. ...
ByScancell
The approval indicates the vaccine production is at a high standard which will help to secure timely patient access to vaccines in the Gulf Cooperation Council (GCC) countries and wider Middle Eastern region. ...
Secondary endpoints include biological activity of the therapeutic vaccine TG4050. CELLULAR IMMUNE RESPONSE WAS EVALUABLE FOR 4 OF THE PATIENTS TREATED WITH TG4050. ...
Abera Bioscience AB is a biotechnology company that develops vaccine candidates based on patented vaccine platforms. The latest vaccine platform makes it possible to produce single, or multiple, antigens in so-called protein bodies. Antigens are the pathogen-specific components of vaccines that elicit immune ...
Kephera’s COVI-QUANT™ test measures the level of IgG antibodies to the spike protein, a viral component which is the key antigen in current COVID-19 vaccines. The test will enable individuals to assess their immune response to vaccination or to infection, and to monitor their antibody level for changes over time. At this point, the ...
Now the company has developed another platform that makes it possible to efficiently produce single or multiple antigens into so-called protein bodies that can be given as a vaccine. Antigens are the components of vaccines that are supposed to elicit immune responses to protect against infectious pathogens or to combat diseases like cancer. The ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive top-line results from a new study evaluating the immune responses generated by an ImplaVax®-enabled unit ...
Additional ingredients (known as adjuvants) are added to increase the body’s reaction and strengthen the immune response. However, additional subunit vaccine boosters may be required to maintain ongoing immunity. ...
MV Biotherapeutics SA (from now on “MV Bio”), a Swiss microbiome biotherapeutics company and Malcisbo AG (from now on “Malcisbo”), a Swiss company developing carbohydrate-based vaccines are proud to announce a collaboration after winning an Innosuisse grant. Malcisbo and MV Bio have previously signed a contract, which gives Malcisbo the exclusive right to use MV Bio ...
The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications: ApyraVax®is a technology platform for live attenuated oral vaccines eliciting protective mucosal responses against enteric pathogens. ...
MV BioTherapeutics participated for the first time to the international event Bio Digital 2020 presenting the company, the pipeline to over 50 companies. “We weren’t sure about the potential success when we applied to the Swiss Pavillon with the sponsoring of Innosuisse” confirms Dr. Fabio Grassi, founder and chairman. “The support we got from Switzerland Global ...
Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands Preliminary clinical data show MV-012-968, the company’s vaccine candidate for respiratory syncytial virus, is heavily attenuated and induces a RSV-specific ...
AJ Vaccines today announced that its adjuvanted IPV vaccine Picovax® has gained marketing approval in Denmark by the Danish Medicines Agency. ...
OncoImmunity teams up with an innovative China based high-tech biotechnology company that has developed a dendritic cell-based vaccine delivery platform. The Chinese vaccine company is developing a personalized cancer vaccine solution with its platform that promises to deliver potent anti-tumor immune responses in ...
And then there is your immune age – the key determinant of future health and response to disease and treatment – quantified now for the first time, creating a potential paradigm shift in drug and vaccine development and medical practice. ...
Here we show that transient depletion of intestinal ATP can dramatically improve high-affinity IgA response against both live and inactivated oral vaccines. Ectopic expression of Shigella flexneri periplasmic ATP-diphosphohydrolase (apyrase) abolishes ATP release by bacteria and improves the specific IgA response against live oral ...
Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded a funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project: “leveraging On t-cell immune resPonse To Improve influenza VACcines”. ...
A new study finds that perfluorinated compounds (PFCs), widely used in manufactured products such as non-stick cookware, waterproof clothing, and fast-food packaging, were associated with lowered immune response to vaccinations in children. It is the first study to document how PFCs, which can be transferred to children prenatally (via the mother) and postnatally ...